One of the well known contract research and manufacturing services (CRAMS) pharmaceutical companies in India, Jubilant Organosys has signed up a joint venture agreement with US multinational drug major firm, Eli Lilly in order to offer development services in drugs to each other.

The joint venture, which will start operationalising before the end of this year, is on similar lines as Chorus, Eli Lilly’s early-stage development division. 

Chorus provides fast drug development services to Eli Lilly by roping in external contract research specialists for specific areas of drug development.

Jubilant Chairman Shyam S Bhartia said, “This unique partnership will be a pioneering effort in leveraging the expertise of a pharma company like Lilly with the emerging development capabilities of Jubilant.” 

He also added that firm will work on drugs in oncology, metabolic disorders, cardiovascular and diabetes segments. It will also provide pre-clinical work besides developing the molecules through phase-II clinical testing therefore providing patients with better and economical health care.